(17 days)
None
Not Found
No
The summary describes a standard blood glucose monitoring system and lacks any mention of AI, ML, image processing, or related concepts.
No
The device is a monitoring system intended for the quantitative measurement of glucose, not for treatment or therapy.
Yes
The device is intended for the quantitative measurement of glucose to aid in monitoring the effectiveness of diabetes control, which is a diagnostic purpose.
No
The intended use describes a "Blood Glucose Monitoring System" which typically involves a physical meter and test strips to measure glucose in blood. The summary does not mention any software-only components or functionalities.
Yes, based on the provided information, the Evencare® Blood Glucose Monitoring System is an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative measurement of glucose in fresh capillary whole blood." This involves testing a biological sample (blood) in vitro (outside the body) to obtain diagnostic information (glucose levels).
- Use Setting: It's intended for use "at home and in clinical settings," which are common environments for IVD devices used for monitoring health conditions.
- Purpose: It's intended "as an aid to monitor the effectiveness of diabetes control," which is a diagnostic purpose related to managing a disease.
The definition of an IVD device generally includes instruments, reagents, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. The Evencare® system fits this description.
N/A
Intended Use / Indications for Use
The Evencare® Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood. It is intended for use outside the body by diabetics at home and in clinical settings as an aid to monitor the effectiveness of diabetes control.
Product codes
NBW, CGA
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
diabetics at home and in clinical settings
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle or bird-like symbol with three curved lines forming its body and head. The logo is surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement.
C and Drug Administration 198 Gaither Road Rockville MD 20850
JUL 0 3 2003
Ms. Andrea Haferkamp Corporate Director of Regulatory Affairs Medline Industries. Inc. One Medline Place Mudelein, IL 60060
Re: K031843 Trade/Device Name: EvenCare ® Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW; CGA Dated: June 13, 2003 Received: June 16, 2003
Dear Ms. Haferkamp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
1
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
2
510(k) Number (if known): K03/843
Device Name: EvenCare® Blood Glucose Monitoring System
Indications for Use:
The Evencare® Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood. It is intended for use outside the body by diabetics at home and in clinical settings as an aid to monitor the effectiveness of diabetes control.
Deany Cooper
Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety
510(k) K031843
(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
OR Over-the-Counter Use v Prescription Use (Per 21 CFR 801.109)
(Optional Format 12-96)